What is Leerink Partnrs’ Estimate for Zymeworks Q1 Earnings?

Zymeworks Inc. (NYSE:ZYME) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Zymeworks in a research report issued on Tuesday, March 18th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.51) per share for the quarter. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($1.30) EPS and FY2027 earnings at ($1.17) EPS.

Several other research analysts have also recently issued reports on the stock. HC Wainwright raised their target price on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Monday, March 10th. JPMorgan Chase & Co. raised shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective for the company in a research note on Monday, December 16th. Wells Fargo & Company raised their target price on Zymeworks from $12.00 to $14.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 19th. Citigroup upped their price target on Zymeworks from $18.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, March 7th. Finally, Lifesci Capital began coverage on Zymeworks in a research report on Tuesday, March 11th. They issued an “outperform” rating and a $30.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Zymeworks Price Performance

ZYME opened at $12.79 on Thursday. Zymeworks has a 1 year low of $7.97 and a 1 year high of $17.70. The stock’s 50 day simple moving average is $13.76 and its 200 day simple moving average is $13.68. The firm has a market cap of $889.89 million, a price-to-earnings ratio of -8.53 and a beta of 1.13.

Insider Transactions at Zymeworks

In other Zymeworks news, Director Ecor1 Capital, Llc acquired 320,690 shares of the business’s stock in a transaction on Tuesday, March 11th. The shares were acquired at an average price of $11.49 per share, for a total transaction of $3,684,728.10. Following the completion of the acquisition, the director now owns 16,040,851 shares in the company, valued at $184,309,377.99. This trade represents a 2.04 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey T. L. Smith sold 11,110 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $14.92, for a total value of $165,761.20. Following the completion of the sale, the executive vice president now directly owns 8,890 shares in the company, valued at approximately $132,638.80. This represents a 55.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders bought 1,507,168 shares of company stock valued at $19,339,774 and sold 89,601 shares valued at $1,336,847. Corporate insiders own 1.92% of the company’s stock.

Hedge Funds Weigh In On Zymeworks

Several institutional investors and hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC increased its stake in Zymeworks by 781.5% during the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company’s stock valued at $25,000 after purchasing an additional 1,524 shares in the last quarter. AlphaQuest LLC grew its holdings in shares of Zymeworks by 480.2% during the fourth quarter. AlphaQuest LLC now owns 2,808 shares of the company’s stock valued at $41,000 after buying an additional 2,324 shares during the last quarter. FMR LLC increased its position in shares of Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after acquiring an additional 1,525 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Zymeworks in the 4th quarter worth approximately $108,000. Finally, Tower Research Capital LLC TRC lifted its position in Zymeworks by 343.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,704 shares of the company’s stock valued at $142,000 after acquiring an additional 7,518 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.